Compare UFPT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | ABCL |
|---|---|---|
| Founded | 1963 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1996 | 2020 |
| Metric | UFPT | ABCL |
|---|---|---|
| Price | $255.48 | $6.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $289.00 | $8.40 |
| AVG Volume (30 Days) | 147.1K | ★ 6.5M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | 10.91 |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $602,797,000.00 | $75,128,000.00 |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $5.72 | $21.85 |
| P/E Ratio | $112.83 | ★ N/A |
| Revenue Growth | 19.50 | ★ 160.56 |
| 52 Week Low | $173.86 | $2.75 |
| 52 Week High | $274.93 | $6.86 |
| Indicator | UFPT | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 71.73 | 70.07 |
| Support Level | $205.96 | $3.27 |
| Resistance Level | $270.31 | N/A |
| Average True Range (ATR) | 9.57 | 0.47 |
| MACD | 1.89 | 0.11 |
| Stochastic Oscillator | 97.01 | 96.95 |
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.